Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3325 - Predictive/prognostic value of circulating regulatory T cell subset in untreated non-small lung cancer patients


10 Oct 2016


Poster display


E. K Vetsika


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


E..K. Vetsika1, F. Koinis1, A. Katsarou1, M. Gioulbasani1, D. Aggouraki1, N. Kentepozidis2, V. Georgoulias1, A. Kotsakis1

Author affiliations

  • 1 Laboratory Of Translational Oncology, School of Medicine, University of Crete, 71110 - Heraklion/GR
  • 2 Department Of Medical Oncology, 251 Air Force General Hospital, 115 25 - Athens/GR


Abstract 3325


Regulatory T-cells (Treg) are highly heterogeneous populations with immune suppressive properties and their role in NSCLC is unknown. The frequency and functionality of the different Treg subtypes in the peripheral blood (PB) of NSCLC patients, as well as their correlation with the patients' clinical outcome was investigated.


PB from 156 chemotherapy-naive patients with stage III/IV NSCLC and 31 healthy donors (HD) was analyzed with flow cytometry for the presence of the different CD4+ Treg subsets [naïve: CD25highCD127−/lowCD152FoxP3lowCD45RO, effector: CD25highCD127−/lowCD152+ FoxP3low CD45RO+ and terminal effector: CD25highCD127CD152+FoxP3+CD45RO+]. Their functionality was tested based on TGF-� and IL-10 production. The patients' clinical outcome (PFS and OS) was correlated with the frequency of Treg subtypes (high vs low expression, according to their percentage > 90% percentile of the HD).


All CD4+ Treg subsets exhibited a highly suppressive activity as revealed by their TGF-ß and IL-10 production. The percentages of naïve Tregs were increased in patients compared to HD (p = 0.02) and were associated with poor clinical outcome. Effector Tregs did not associated with response to treatment; Higher levels of Terminal effector Tregs were correlated with improved clinical response (p= 0.04). Normal levels of naïve and effector Treg, at baseline, were associated with longer PFS and OS compared to those with high levels (p= 0.03 and p = 0.02; p= 0.03 and p= 0.03, respectively). In contrast, high frequency of the terminal effector Treg, at baseline, was correlated with longer PFS (p = 0.03) and OS (p = 0.04) compared to low frequency.


It is demonstrated, for the first time, that particular CD4+ Treg subtypes are increased in NSCLC patients and are associated to the clinical outcome. Their depletion or blocking their migration to the tumour site may be an effective therapeutic strategy.

Clinical trial identification


Legal entity responsible for the study



Laboratory of Translational Oncology, School of Medicine, University of Crete


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings